CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it.

1. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.Clinical pharmacology and therapeutics · 2017
   Guideline
2. Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.Pharmacogenomics · 2016
   Pooled it
3. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.The pharmacogenomics journal · 2013
   Pooled it
4. Precision Medicine Approaches to Mental Health Care.Physiology (Bethesda, Md.) · 2023
   Review
5. The pharmacogenetics ofFrontiers in pharmacology · 2023
   Article
6. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.Expert opinion on drug metabolism & toxicology · 2022
   Review
7. A one-year follow-up study of treatment-compliant suicide attempt survivors: relationship of CYP2D6-CYP2C19 and polypharmacy with suicide reattempts.Translational psychiatry · 2022
   Article
8. Consequences ofFrontiers in psychiatry · 2019
   Review
9. Value of Supportive Care Pharmacogenomics in Oncology Practice.The oncologist · 2018
   Review
10. High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina.The pharmacogenomics journal · 2017
    Article
11. High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies.The pharmacogenomics journal · 2016
    Article
12. Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs.Dialogues in clinical neuroscience · 2016
    Review
13. Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder.Neuropsychiatric disease and treatment · 2016
    Article
14. A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances.The pharmacogenomics journal · 2015
    Article
15. Towards the clinical implementation of pharmacogenetics in bipolar disorder.BMC medicine · 2014
    Article
16. CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials.British journal of clinical pharmacology · 2014
    Review
17. Impact of cytochrome P450 genes on suicide attempt and risk.European archives of psychiatry and clinical neuroscience · 2013
    Article
18. The association between CYP2D6 genotype and switching antipsychotic medication to clozapine.European journal of clinical pharmacology · 2013
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

9 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as